Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
ORMP's Cash-to-Debt is ranked higher than
87% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. ORMP: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ORMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.06  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.50
ORMP's Equity-to-Asset is ranked lower than
69% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ORMP: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
ORMP' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.57 Max: 0.85
Current: 0.5
0.5
0.85
Piotroski F-Score: 5
Altman Z-Score: 1.66
Beneish M-Score: 1.19
WACC vs ROIC
6.89%
-71.30%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -522.91
ORMP's Operating Margin % is ranked lower than
71% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. ORMP: -522.91 )
Ranked among companies with meaningful Operating Margin % only.
ORMP' s Operating Margin % Range Over the Past 10 Years
Min: -1561.62  Med: -1561.62 Max: -522.91
Current: -522.91
-1561.62
-522.91
Net Margin % -572.52
ORMP's Net Margin % is ranked lower than
74% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. ORMP: -572.52 )
Ranked among companies with meaningful Net Margin % only.
ORMP' s Net Margin % Range Over the Past 10 Years
Min: -1710.45  Med: -1710.45 Max: -572.52
Current: -572.52
-1710.45
-572.52
ROE % -51.29
ORMP's ROE % is ranked lower than
56% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. ORMP: -51.29 )
Ranked among companies with meaningful ROE % only.
ORMP' s ROE % Range Over the Past 10 Years
Min: -8090  Med: -73.14 Max: -31.7
Current: -51.29
-8090
-31.7
ROA % -30.49
ORMP's ROA % is ranked higher than
50% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. ORMP: -30.49 )
Ranked among companies with meaningful ROA % only.
ORMP' s ROA % Range Over the Past 10 Years
Min: -306.29  Med: -61.8 Max: -30.04
Current: -30.49
-306.29
-30.04
ROC (Joel Greenblatt) % -56.90
ORMP's ROC (Joel Greenblatt) % is ranked higher than
66% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. ORMP: -56.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ORMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -313200  Med: -224.73 Max: 5234
Current: -56.9
-313200
5234
3-Year EBITDA Growth Rate 7.10
ORMP's 3-Year EBITDA Growth Rate is ranked higher than
56% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. ORMP: 7.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ORMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.7  Med: 7.1 Max: 57.2
Current: 7.1
-10.7
57.2
3-Year EPS without NRI Growth Rate 13.80
ORMP's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. ORMP: 13.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ORMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -26.3  Med: 5.5 Max: 188.4
Current: 13.8
-26.3
188.4
GuruFocus has detected 2 Warning Signs with Oramed Pharmaceuticals Inc $ORMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ORMP's 30-Y Financials

Financials (Next Earnings Date: 2017-11-30 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ORMP Guru Trades in

ORMP Guru Trades in

ORMP Guru Trades in

Q2 2017

ORMP Guru Trades in Q2 2017

Jim Simons 25,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XTAE:CBI, NAS:PSTI, NAS:MDWD, XTAE:EVGN, NAS:VBLT, NAS:BLRX, XTAE:RDHL, NAS:GLMD, AMEX:PLX, NAS:CGEN, XTAE:KMDA, NAS:FOMX, XTAE:APOP, XTAE:NTEC, OTCPK:TOMDF, XTAE:BVXV, NAS:ADHD, XTAE:CFBI, XTAE:TRPX, XTAE:KTOV » details
Traded in other countries:OJU1.Germany, ORMP.Switzerland,
Headquarter Location:Israel
Oramed Pharmaceuticals Inc is a pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet.

Oramed Pharmaceuticals Inc was incorporated on April 12, 2002, under the laws of the state of Nevada. It is a pharmaceutical company engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. It filed two additional provisional patents for a suppository application to its technology portfolio. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.

Top Ranked Articles about Oramed Pharmaceuticals Inc

Oramed Announces Successful Meeting with FDA for Oral Insulin
Oramed to Present at the Rodman & Renshaw Global Investment Conference
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Diabetes accounts for nearly 10% of US health care spending
Total U.S. health care spending in 2015 was an astronomical $3.2 trillion. That is 16% of the entire national debt. As much as we blame the prices of new drugs for this gargantuan sum, one of the biggest chunks of it comes from diabetes, a disease whose treatment has not changed all that much since 1922. According to the American Diabetes Association, diabetes accounts for $322 billion in total U.S. health care spending as of 2016. Read more...
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs
Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
Oramed to Present at the American Diabetes Association 77th Scientific Sessions
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Oramed Granted Canadian Patent for GLP-1 Analog Capsule
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 52.46
ORMP's Price-to-Owner-Earnings is ranked lower than
54% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. ORMP: 52.46 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ORMP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.74  Med: 31.66 Max: 54.13
Current: 52.46
9.74
54.13
PB Ratio 6.37
ORMP's PB Ratio is ranked lower than
58% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. ORMP: 6.37 )
Ranked among companies with meaningful PB Ratio only.
ORMP' s PB Ratio Range Over the Past 10 Years
Min: 2.44  Med: 3.68 Max: 6.57
Current: 6.37
2.44
6.57
PS Ratio 57.58
ORMP's PS Ratio is ranked lower than
79% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. ORMP: 57.58 )
Ranked among companies with meaningful PS Ratio only.
ORMP' s PS Ratio Range Over the Past 10 Years
Min: 44.81  Med: 66.74 Max: 930
Current: 57.58
44.81
930
Price-to-Free-Cash-Flow 40.80
ORMP's Price-to-Free-Cash-Flow is ranked lower than
59% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. ORMP: 40.80 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ORMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.29  Med: 25.46 Max: 42.07
Current: 40.8
9.29
42.07
Price-to-Operating-Cash-Flow 40.80
ORMP's Price-to-Operating-Cash-Flow is ranked lower than
61% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. ORMP: 40.80 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ORMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.29  Med: 25.46 Max: 42.07
Current: 40.8
9.29
42.07
EV-to-EBIT -11.36
ORMP's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. ORMP: -11.36 )
Ranked among companies with meaningful EV-to-EBIT only.
ORMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.3  Med: -9.5 Max: -6.8
Current: -11.36
-14.3
-6.8
EV-to-EBITDA -11.37
ORMP's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. ORMP: -11.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
ORMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.3  Med: -9.5 Max: -6.8
Current: -11.37
-14.3
-6.8
EV-to-Revenue 55.55
ORMP's EV-to-Revenue is ranked lower than
74% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. ORMP: 55.55 )
Ranked among companies with meaningful EV-to-Revenue only.
ORMP' s EV-to-Revenue Range Over the Past 10 Years
Min: 42  Med: 62.1 Max: 898.9
Current: 55.55
42
898.9
Current Ratio 5.23
ORMP's Current Ratio is ranked higher than
63% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. ORMP: 5.23 )
Ranked among companies with meaningful Current Ratio only.
ORMP' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 7.09 Max: 67.68
Current: 5.23
0.02
67.68
Quick Ratio 5.23
ORMP's Quick Ratio is ranked higher than
65% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. ORMP: 5.23 )
Ranked among companies with meaningful Quick Ratio only.
ORMP' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 7.09 Max: 67.68
Current: 5.23
0.02
67.68

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.40
ORMP's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. ORMP: -18.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ORMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -44.9  Med: -18.4 Max: -7.6
Current: -18.4
-44.9
-7.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 19.79
ORMP's Price-to-Net-Current-Asset-Value is ranked lower than
67% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. ORMP: 19.79 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ORMP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.56  Med: 8.17 Max: 94.5
Current: 19.79
2.56
94.5
Price-to-Tangible-Book 6.38
ORMP's Price-to-Tangible-Book is ranked higher than
50% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ORMP: 6.38 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ORMP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.19  Med: 6.64 Max: 76.36
Current: 6.38
2.19
76.36
Price-to-Median-PS-Value 0.86
ORMP's Price-to-Median-PS-Value is ranked higher than
83% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. ORMP: 0.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ORMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68  Med: 1.57 Max: 10.58
Current: 0.86
0.68
10.58
Earnings Yield (Greenblatt) % -8.84
ORMP's Earnings Yield (Greenblatt) % is ranked lower than
57% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. ORMP: -8.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ORMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14.7  Med: -10.5 Max: -7
Current: -8.84
-14.7
-7

More Statistics

Revenue (TTM) (Mil) $2.19
EPS (TTM) $ -0.96
Beta0.81
Short Percentage of Float1.72%
52-Week Range $5.70 - 10.00
Shares Outstanding (Mil)13.32

Analyst Estimate

Aug17 Aug18
Revenue (Mil $) 2 3
EPS ($) -0.99 -1.27
EPS without NRI ($) -0.99 -1.27
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ORMP

Headlines

Articles On GuruFocus.com
Oramed Announces Successful Meeting with FDA for Oral Insulin Sep 05 2017 
Oramed to Present at the Rodman & Renshaw Global Investment Conference Aug 29 2017 
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Aug 21 2017 
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs Jul 18 2017 
Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017 Jul 12 2017 
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program Jul 11 2017 
Oramed Remains Strong With Near and Long-Term Catalysts Jun 13 2017 
Oramed to Present at the American Diabetes Association 77th Scientific Sessions Jun 06 2017 
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Po Jun 05 2017 
Oramed Granted Canadian Patent for GLP-1 Analog Capsule May 09 2017 

More From Other Websites
Oramed (ORMP): Successful Meeting with FDA for Oral Insulin Sep 05 2017
Oramed Announces Successful Meeting with FDA for Oral Insulin Sep 05 2017
Oramed to Present at the Rodman & Renshaw Global Investment Conference Aug 29 2017
3 Companies Aiming to Significantly Reduce Diabetes Treatment Costs Aug 21 2017
Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs Jul 18 2017
Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017 Jul 12 2017
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program Jul 11 2017
Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q3, 2017 By the Numbers : July 10, 2017 Jul 10 2017
Oramed reports 3Q loss Jul 06 2017
Oramed Announces Dual-Listing on Tel Aviv Stock Exchange Jul 05 2017
Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule Jun 27 2017
Oramed to Present at the American Diabetes Association 77th Scientific Sessions Jun 06 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for... Jun 05 2017
Oramed to Present at Conferences Next Week May 18 2017
Oramed Granted Canadian Patent for GLP-1 Analog Capsule May 09 2017
Oramed Pharmaceuticals, Inc. :ORMP-US: Earnings Analysis: Q2, 2017 By the Numbers : May 5, 2017 May 05 2017
Oramed (ORMP) to Conduct Human Study for New Oral Leptin Capsule May 02 2017
Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule May 02 2017
Oramed Gaining Strength in Oral Diabetes Market May 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}